



NEWS RELEASE

International Patent Publication for DEF201 Broad Spectrum Antiviral and Immune Stimulator

Web Site Release

December 16, 2010

Toronto - Defyrus Inc. today announced the publication of its international patent application entitled "*Administration of Interferon for Prophylaxis Against or Treatment of Pathogenic Infection*" PCT/CA2010/000844. The priority date of June 9, 2009 had been established previously for this application by the US Patent & Trademark Office. The invention provides compositions of matter and methods for the prophylaxis or treatment of pathogenic viral infections i.e. biological weapons or endemic diseases, using adenoviral-vectored human interferon genes delivered intranasally which circumvents pre-existing immunity. This proprietary technology has been shown to be highly effective against 7 lethal viral families including Ebola & Lassa Hemorrhagic Fevers, Pox, Yellow Fever, SARS and Venezuelan, Eastern and Western equine encephalitis (VEE). Intellectual property rights have been assigned by the inventors Turner & Ennis to Defyrus Inc. as per company policy.

"International patents are the foundation for Defyrus' commercial drug development and sales activities", stated Dr. Jeffrey Turner, President & CEO, Defyrus, "this intellectual property further enhances Defyrus' existing issued patent portfolio with many indications reduced to practice".

About Defyrus Inc.

Defyrus is a private, life sciences biodefence company that collaborates with military and public health R&D partners in the United States, United Kingdom, and Canada to develop broad spectrum anti-viral drugs and immune stimulator to improve vaccine performance as medical countermeasures to viral threats of military and public health interest. www.defyrus.com

###

For further information:

Dr. Jeffrey D. Turner
President & CEO
Tel: (613) 674-1138
info@defyrus.com

Mr. Dana Rath
Chief Financial Officer
Tel: (514) 939-2531
info@defyrus.com